Analysts Anticipate Tandem Diabetes Care Inc (TNDM) Will Post Quarterly Sales of $53.88 Million

Equities analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will announce sales of $53.88 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Tandem Diabetes Care’s earnings, with estimates ranging from $50.80 million to $57.03 million. Tandem Diabetes Care posted sales of $40.29 million during the same quarter last year, which would suggest a positive year over year growth rate of 33.7%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 7th.

On average, analysts expect that Tandem Diabetes Care will report full-year sales of $164.22 million for the current fiscal year, with estimates ranging from $163.74 million to $164.70 million. For the next financial year, analysts anticipate that the business will report sales of $207.76 million, with estimates ranging from $194.70 million to $216.19 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.28). The firm had revenue of $46.30 million during the quarter, compared to analysts’ expectations of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. The firm’s revenue for the quarter was up 71.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($3.09) EPS.

Several equities analysts have commented on the stock. Lake Street Capital set a $60.00 price target on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Saturday. Craig Hallum set a $59.00 price target on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Friday, November 2nd. Oppenheimer set a $57.00 price target on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Friday, November 2nd. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Finally, Dougherty & Co boosted their price target on shares of Tandem Diabetes Care from $45.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, September 26th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Tandem Diabetes Care has an average rating of “Buy” and a consensus price target of $44.27.

Several hedge funds have recently modified their holdings of the stock. US Bancorp DE lifted its position in Tandem Diabetes Care by 397.8% in the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock valued at $107,000 after acquiring an additional 1,989 shares during the last quarter. Meeder Asset Management Inc. lifted its position in Tandem Diabetes Care by 1,921.6% in the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock valued at $116,000 after acquiring an additional 2,575 shares during the last quarter. Wells Fargo & Company MN lifted its position in Tandem Diabetes Care by 11.3% in the third quarter. Wells Fargo & Company MN now owns 26,968 shares of the medical device company’s stock valued at $1,155,000 after acquiring an additional 2,734 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new stake in Tandem Diabetes Care in the third quarter valued at $174,000. Finally, Creative Planning lifted its position in Tandem Diabetes Care by 19.7% in the third quarter. Creative Planning now owns 25,129 shares of the medical device company’s stock valued at $1,077,000 after acquiring an additional 4,129 shares during the last quarter. Hedge funds and other institutional investors own 62.80% of the company’s stock.

NASDAQ:TNDM opened at $36.80 on Wednesday. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -2.86 and a beta of 0.53. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $52.55.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply